Mirikizumab is associated with improvements in bowel urgency and quality of life in moderately-to-severely active ulcerative colitis: 28-week phase 3b results from the LUCENT-URGE trial.
Long M, Laharie D, Rogler G, Navabi S, Vadhariya A, Eastman WJ, Tian T, Bleakman AP, Armuzzi A
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.